Thursday, 5 November 2026European Markets

ASETEK Stock Went Up By Over 10% So Far Today

Loading stream...

(VIANEWS) - Shares of ASETEK (Oslo Børs Benchmark Index_GI: ASTK.OL) rose by a staggering 10.95% to kr8.92 at 11:22 EST on Tuesday, after four consecutive sessions in a row of gains. Oslo Børs Benchmark Index_GI is jumping 0.74% to kr1,234.98, following the last session's downward trend. This seems, at the moment, a somewhat bullish trend exchanging session today.

About ASETEK

Asetek A/S, together with its subsidiaries, engages in the designing, developing, and marketing of liquid cooling solutions in Asia, Europe, and the Americas. The company operates through Liquid cooling, Data center and SimSports segments. Its products are used in personal computers, servers, and data centers to provide improved performance, acoustics, and energy efficiency. It serves original equipment manufacturers, resellers, and channel partners. The company was founded in 1997 and is headquartered in Aalborg, Denmark.

Earnings Per Share

As for profitability, ASETEK has a trailing twelve months EPS of kr-0.98.

More news about ASETEK (ASTK.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com